SecurityJCS / Communications Systems, Inc. (203900105)
CEOLacey Roger HD
IndustryTelephone and Telegraph Apparatus
Institutional Owners30
Institutional Shares2,908,661 - 31.79%
Common Shares Outstanding9,149,924 shares (as of 2018-06-30)
Institutional Value$ 11,173,000 USD

Institutional Stock Ownership and Shareholders

JCS / Communications Systems, Inc. Institutional Ownership

Communications Systems, Inc. (NASDAQ:JCS) has 30 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,908,661 shares. Largest shareholders include Gamco Investors, Inc. Et Al, Dimensional Fund Advisors Lp, Renaissance Technologies LLC, Gabelli Funds Llc, Vanguard Group Inc, BlackRock Inc., BlackRock Institutional Trust Company, N.A., Ancora Advisors, LLC, Bridgeway Capital Management Inc, and Gould Asset Management Llc /ca/.
Communications Systems, Inc. (NASDAQ:JCS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-08-10 13F-HR GABELLI FUNDS LLC 390,000 391,416 0.36 1,470 1,491 1.43
2018-08-08 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 53,328 0 -100.00 196 0 -100.00
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 14,540 13,251 -8.87 53 50 -5.66
2018-08-14 13F-HR MACQUARIE GROUP LTD 30,230 22,030 -27.13 114 84 -26.32
2018-08-10 13F-HR GAMCO INVESTORS, INC. ET AL 695,110 675,104 -2.88 2,620 2,572 -1.83
2018-08-14 13F-HR AMERIPRISE FINANCIAL INC 22,277 27,293 22.52 84 104 23.81
2018-08-10 13F-HR Ancora Advisors, LLC 98,298 102,004 3.77 371 389 4.85
2018-08-10 13F-HR DIMENSIONAL FUND ADVISORS LP 498,489 473,911 -4.93 1,829 1,806 -1.26
2018-08-14 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 148,600 83,900 -43.54 545 320 -41.28
2018-08-14 13F-HR PANAGORA ASSET MANAGEMENT INC 9,273 6,030 -34.97 34 23 -32.35
2018-07-11 13F-HR BREMER TRUST NATIONAL ASSOCIATION 16,150 16,150 0.00 61 62 1.64
2017-02-10 13F-HR BlackRock Investment Management, LLC 1,353 1,353 0.00 6 6 0.00
2018-07-18 13F-HR Fny Investment Advisers, Llc 45 0
2018-09-18 13F-HR/A NORTHERN TRUST CORP 23,118 23,218 0.43 87 88 1.15
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 26,093 26,283 0.73 95 100 5.26
2018-08-14 13F-HR BARCLAYS PLC 6,000 23
2018-08-09 13F-HR BlackRock Inc. 133,393 135,790 1.80 503 517 2.78
2018-07-26 13F-HR Advisornet Financial, Inc 1,010 10 -99.01 4 0 -100.00
2018-08-14 13F-HR MORGAN STANLEY 0 80 0 0
2018-08-15 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 26,400 26,400 0.00 97 101 4.12
2018-08-14 13F-HR ROYAL BANK OF CANADA 5,720 5,720 0.00 22 22 0.00
2018-08-14 13F-HR UBS Group AG 4,383 1,163 -73.47 17 4 -76.47
2018-08-14 13F-HR VANGUARD GROUP INC 159,922 214,622 34.20 587 818 39.35
2018-08-14 13F-HR Tower Research Capital LLC (TRC) 0 1,676 0 6
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 0 1 0 0
2018-08-14 13F-HR DEUTSCHE BANK AG\ 15,665 25,038 59.83 59 95 61.02
2018-08-13 13F-HR GOULD ASSET MANAGEMENT LLC /CA/ 28,138 29,008 3.09 106 111 4.72
2018-08-13 13F-HR Renaissance Technologies LLC 445,265 1,678
2018-07-26 13F-HR Alpha Cubed Investments, LLC 23,044 88
2018-08-14 13F-HR Resources Investment Advisors, Inc. 252 0 -100.00 1 0 -100.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 109,771 109,771 0.00 523 508 -2.87
2017-02-10 13F-HR BlackRock Fund Advisors 22,331 23,085 3.38 106 107 0.94

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

L3: Business Restructuring Provides Opportunity

2018-08-27 seekingalpha
The company is growing revenues in the high single digits and undergoing structural changes to streamline business units and better position for growth.

Harris Corporation: Outperforming The Defense Group And Approaching Fair Value

2018-08-21 seekingalpha
The share price is approaching fair value levels and there is only about 6% of upside from current share levels.

Ultralife Corporation (ULBI) CEO Mike Popielec on Q2 2018 Results - Earnings Call Transcript

2018-08-04 seekingalpha
Good day, and welcome to the Ultralife Corporation Second Quarter 2018 Earnings Conference Call. At this time, for opening remarks and introduction, I'd like to turn the call over to Ms. Jody Burfening. Please go ahead.

Harris (HRS) Q4 2018 Results - Earnings Call Transcript

2018-07-31 seekingalpha
Greetings, and welcome to the Harris Corporation Fourth Quarter Fiscal Year 2018 Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.

Firm founded by Trump aides scored deals with Altria, Citgo

2018-05-15 cnbc
Michael Cohen wasn't the only one with ties to President Donald Trump trying to rope in billion-dollar companies. Former campaign advisors at Avenue Strategies were doing the same — with broader reach and apparently much more success. (1-0)

Ultralife Corp's (ULBI) CEO Michael Popielec on Q1 2018 Results - Earnings Call Transcript

2018-05-06 seekingalpha
Good day, and welcome to this Ultralife Corporation First Quarter 2018 Earnings Release Conference Call. This call is being recorded. At this time, for opening remarks and introductions, I'd like to turn the call over to Jody Burfening. Please go ahead, ma'am. (3-0)

CUSIP: 203900105